Eyam Vaccines Secures Grant to Advance Gemini Expression Platform

Vancouver, BC / ACCESSWIRE / September 10, 2024 / Eyam Vaccines and Immunotherapeutics has announced a new grant from the Bill & Melinda Gates Foundation. This grant aims to support the further development of their Gemini expression platform. The project seeks to enhance the platform's ability to deliver durable expression of a protein therapeutic.

The study will use a monoclonal antibody to evaluate the platform's effectiveness in generating sustained protein expression. Eyam's CEO, Ryan M. Thomas, stated that this grant is a significant step for the Gemini platform, potentially unlocking new opportunities in developing long-lasting, cost-effective treatments for various diseases.

Dr. Terry Pearson, member of Eyam's Board of Directors, highlighted the platform's potential to improve monoclonal antibody therapies. The technology could enhance treatment effectiveness and reduce the need for frequent dosing, thus improving patient compliance.

The Gemini Platform offers the possibility of sustained therapeutic effects with minimal dosing, potentially transforming the delivery of protein-based therapies. Dr. Wilfred Jefferies, Chief Scientific Officer, emphasized that the Gemini Platform represents a significant advancement in therapeutic delivery.

The proof-of-concept study will commence immediately, focusing on preclinical evaluations to validate the platform's long-term protein expression capabilities. If successful, it could lead to further exploration in various therapeutic areas beyond infectious diseases.